Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8XP, United Kingdom
NCT Number: NCT02457156
The purpose of this study is to compare two different techniques of performing a pancreatic anastomosis; Cattell-Warren versus Blumgart to determine if a Blumgart anastomosis reduces pancreatic remnant leak, post-operative complications and overall length of hospital stay.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Liverpool, Merseyside, L7 8XP, United Kingdom
This is a randomised controlled, phase III, double blinded, multicentre clinical trial comparing Cattell-Warren (CWA) versus. Blumgart (BA) methods of pancreaticojejunostomy following pancreaticduodenectomy for supected malignancy of the pancreatic head.
The primary objective of the trial is to establish if the Blumgart anastomosis reduces pancreatic remnant leak and in turn complications, hospital stay, cost and promote enhanced recorvery programs.
506 patients (253 patients per treatment arm) will be recruited from approximately 7 centres throughout the United Kingdom.
Patients recommended for resection who provide written informed consent will be randomised to one of the following treatment arms on the day of surgery by the surgeon:
Arm A: Blumgart method of panreaticojejunostomy. Arm B: CattellWarren method pf pancreaticojejunostomy.
Randomisation will be undertaken intra-operatively, following pancreatic head excision, just prior to pancreatic head remnant reconstruction.
Patients will be assessed post operatively on days 3 to 7 and on day of dishcharge from hospital. Patients will continue to be followed up in the outpatient setting at 3, 6 and 12 months post surgery.
All laboratory and physical assessments performed will be in line standard care.
Blood samples for the translational study will be taken subject to informed consent pre-operatively and post-operatively 5 days after surgery.
A histological (H&E stained) slide of the pancreatic transection margin should be taken as routine. This will be requested from each patient for central pathology review to assess the amount of fibrosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Pancreatico-jejunostomy
Other names: Pancreatico-jejunostomy
Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
Other names: Sandostatin
Time frame: Assessed up to 3 months after surgery.
Post-operative pancreatic fistula are defined as any abnormal connection between the pancreatic duct epithelium and another epithelised surface, which contains pancreatic derived, enzyme rich fluid. This will be assessed up to 3 months following surgery on inpatient days 3-7, day of discharge (expected to be 1 - 5 weeks after surgery) and 3 month follow up.
Time frame: 3, 6 and 12 month follow up
Time frame: Death due to any cause during the study will be recorded
Time frame: Post operative day 3, 5, 7, and the day of discharge, which is expected to be between 1 - 5 weeks after surgery.
Time frame: Post operative day 3, 5, 7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3, 6 and 12 month follow up
Time frame: The day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3 month follow up.
Time frame: post operative days 3-7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3 month follow-up
Time frame: Day of surgery
Time frame: day of surgery, post operaive day 3, 5, 7 and the day of discharge, which is expected to be between 1 - 5 weeks after surgery
Time frame: Up to 12 months after surgery
Time frame: Post operative day 3, 5, 7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow up
Time frame: The day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow-up
Time frame: Enrolment, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow-up
Time frame: Enrolment, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow-up
University of Liverpool
Other
PANasta Trial Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy - a Double Blinded Multi Centred Trial
Acronym: PANasta
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05675059
Digestive System Diseases, Digestive System Neoplasms
Tampa, Florida, United States
View Trial DetailsNCT03410030
Digestive System Diseases, Digestive System Neoplasms
Scottsdale, Arizona, United States
View Trial DetailsNCT04553926
Adnexal Diseases, Breast Cancer
Ansan, South Korea
View Trial DetailsNCT03096054
Breast Cancer (Triple Negative Type), Breast Diseases
Belfast, United Kingdom
View Trial Details